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B, and stand-alone Part D plan coverage in the 12-months pre- and post-index 
date and have > 1 claim for psoriasis (ICD-9CM code 696.1) in the 12-month pre-
index period. Exclusion criteria included presence of other conditions for which 
these biologics are indicated, or receipt of any biologic in the 12-months pre-
index. Adherence to index biologic was defined as patients with proportion of 
days covered (PDC) > 0.80 during the 12-months post-index. Logistic regression 
analyses were conducted to determine the factors associated with being adher-
ent. RESULTS: Our sample included 2,707 patients newly initiating biologics. 
Overall, mean PDC for any index biologic was 0.61 and only 38% were adherent to 
their index biologic in the 12 months following initiation. Mean PDC and adherence 
rates were similar between physician-administered and self-administered agents, 
but there were several differences by index biologic. Mean PDCs were 0.66 for 
infliximab (N= 318), 0.70 for ustekinumab (N= 280), 0.63 for adalimumab (N= 1084), 
and 0.56 for etanercept (N= 1025). Adherence rates were 49%, 43%, 41%, and 29%, 
respectively. Logistic regression indicated that older age, and female gender 
were associated with poor adherence. Index biologic was also a significant factor 
associated with being adherent. CONCLUSIONS: Adherence with biologic treat-
ment for psoriasis is poor in the Medicare population with rates < 50% across all 
biologics.
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ObjECTIvES: There is a plethora of interventions for the treatment of overactive 
bladder syndrome, including a course of supervised pelvic floor muscle training, 
behavioral therapy, anticholinergic medication, sacral nerve stimulation, and more 
recently, botulinum toxin type A (BoNT-A) and beta-3-adrenergic agonists. Though 
there is a large and diverse range of treatment options, there is little information 
of which of them is the most clinically effective. This is largely because trials often 
compare interventions with a placebo or with interventions of the same class; and 
so there are a limited number of trials that compare interventions of different 
classes, and thus different approaches on a head-to-head basis. METhOdS: We 
searched Medline, EMBASE, Cochrane Incontinence Group Specialized Register, 
and all relevant references for randomized controlled trials evaluating interven-
tions for OAB through to October 2014. Using Bayesian Markov Chain Monte Carlo 
(MCMC) methods, we applied a hierarchical network meta-analysis that accounts 
for the exchangeability of treatment effects between different modes of admin-
istration (e.g. extended and immediate release), between treatments within the 
same class (e.g. anticholinergics) and the residual between-study heterogeneity. 
We further adjusted for differences in baseline severity of the patient population, 
as different interventions are used at varying times in the treatment pathway. 
The primary outcomes of interest were mean change from baseline for voiding, 
urgency, and incontinence episodes. RESULTS: Preliminary results show that for 
voiding and urgency episodes, BoNT-A 200u was the most effective intervention. 
BoNT-A 300u was the most effective intervention for reducing incontinence epi-
sodes. CONCLUSIONS: BoNT-A was found to be the most effective intervention for 
reducing symptoms of OAB. Accounting for the exchangeability between different 
modes of administration and treatments within in the same class sufficiently 
increases the precision in the treatment effect estimates but maintains the inter-
pretability of the individual and diverse range of treatment options.
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ObjECTIvES: LUTS associated with BPH (LUTS/BPH) in men may present as a 
combination of voiding, storage and post-micturition symptoms. UK prescribers 
have proposed two areas of improvement to current care: first, acknowledging 
that α -blocker monotherapy may not address bothersome storage symptoms; and 
second, building confidence in primary care to prescribe drug combinations for 
mixed symptoms. We built a model to evaluate the potential budget savings from 
implementing these treatment pathway changes. METhOdS: A model was built 
in Microsoft® Excel to depict a simplified LUTS care pathway, aligned with current 
clinical practice and NICE treatment recommendations in a hypothetical cohort 
of 10,000 men with LUTS/BPH who have moderate-to-severe storage and voiding 
symptoms. The budget impact of a proposed pathway redesign was calculated, 
which could adjust the number of men diagnosed and managed in primary care. 
Men could receive a range of treatment options, and if symptoms persisted, could 
ultimately be recommended for surgery. RESULTS: The model estimated several 
annual cost savings: –£2,964,169 by increasing the proportion of men diagnosed 
in primary rather than secondary care from 30% to 40%; –£1,623,701 by increasing 
the proportion of men receiving initial LUTS treatment in primary rather than 
secondary care from 50% to 60%; and –£4,114,738 by increasing the proportion of 
men receiving combination rather than monotherapy from 6% to 20%. A combi-
nation of all proposed changes resulted in a saving of –£8,208,061. Varying drug 
choice or cost were shown to have minimal financial impact. CONCLUSIONS: The 
pathway redesign indicates substantial savings. Specifically, increasing primary 
care diagnosis and treatment of LUTS/BPH symptoms would avoid referral costs 
and potentially delay surgery, while increasing general practitioner confidence 
per-prescription of branded (Cipro) ciprofloxacin was $149.34. The sharp decrease 
in the utilization of Trovan can be explained by the withdrawal from the market 
in 2001 because of risk of liver failure. CONCLUSIONS: Increased expenditures 
for fluoroquinolones paralleled with increased utilization. Generic drug utiliza-
tion increased dramatically after brand-name patent expiration. Fluoroquinolone 
drug utilization might be also associated with its safety profile and related disease 
treatment guidelines.
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ObjECTIvES: Obesity is associated with increased risk of soft tissue infection and 
clinical failure; however, the association between obesity and longer-term clinical 
outcomes in ABSSSI patients is not well-studied. This study compared hospital read-
mission rates between obese and non-obese ABSSSI patients. METhOdS: Adults 
(> 18 years) hospitalized with ≥ 1 primary ABSSSI diagnosis were selected from the 
Cerner HealthFacts electronic medical records database (2009-2013). The first pri-
mary ABSSSI inpatient admission was defined as the index admission. Patients 
were categorized into obese (BMI> 30) and non-obese cohorts at the index admis-
sion. Proportions of patients with all-cause and ABSSSI-related readmission to the 
same hospital within 30 days were compared between the cohorts descriptively 
(in subgroups defined by gender, age, and causative pathogen) and using multi-
variable logistic regression adjusting for hospital size, demographics, insurance 
type, causative pathogen, and important comorbidities. RESULTS: 5,823 obese and 
5,882 non-obese patients were identified. Fewer obese patients were male (47.8% vs 
55.8%), ≥ 65 years old (28.2% vs 34.3%), and admitted to teaching hospitals (70.7% vs 
73.4%). Same-hospital 30-day readmission rates were higher for obese patients for 
both all-cause (12.9% vs 11.8%, p= 0.085) and ABSSSI-related (5.3% vs 4.0% p= 0.0019) 
readmissions. ABSSSI-related readmission rates remained significantly higher for 
obese patients among males (5.1% vs 3.8%, p= 0.0086), younger patients (age < 65 
years, 5.0% vs 3.6%, p= 0.0026), and those not infected with methicillin-resistant 
staphylococcus aureus (5.3% vs 4.2%, p= 0.0049). In multivariable regressions, obese 
patients had higher odds of 30-day readmission for all-cause readmissions (obese 
vs non-obese: OR= 1.10, p= 0.0944) and significantly higher odds of ABSSSI-related 
readmissions (OR= 1.28, p= 0.0073). CONCLUSIONS: Obese ABSSSI patients experi-
enced higher rates of same-hospital ABSSSI-related readmission compared with 
non-obese patients. The association persisted in male, age < 65, and non-MRSA sub-
groups and remained significant after adjustment for confounding. Further studies 
are warranted to estimate total readmission rates, which may be underestimated 
by same-hospital readmission rates.
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ObjECTIvES: Identify and analyze the level of scientific production in the oral 
health field worldwide, by applying quantitative assessment counting meth-
ods and bibliometric analysis. METhOdS: The review was realized using the 
Scopus database, given its greater coverage according to The Academic Database 
Assessment Tool. The results were analyzed through production, dissemination, 
collaboration and bibliometric indicators, which considered the trends in publica-
tion, authors, document type, workspace, magazines, country, number of citations, 
impact factor, h-index and dissemination network. A descriptive analysis was 
performed from the public policy context in oral health, in addition to the estima-
tion of trends and state of the art investigation. RESULTS: 1.727 scientific articles 
were found through searching terms associated with “oral health” AND “public 
health” AND “public policy”. The annual growth function provided an increased 
trend since 2000. The United States, Brazil and the United Kingdom were the 
countries with the highest impact and development in the oral health field, pro-
viding 40.7% of the total references found. The production is allied especially to 
universities and research groups, mainly the University of Sao Paulo, University of 
Adelaide and University of North Carolina at Chapel Hill. The areas of knowledge 
with the greater incidence were: medicine (44.1%), Dentistry (39%) and social sci-
ences (4.8%). The search for oral health had an index h: 46. CONCLUSIONS: The 
scientific production in oral health topics shows increasing development and 
institutional affluence. It is expected that the oral health problems analyzed would 
have solutions and support from the government of the region and the allocation 
of resources for health.
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ObjECTIvES: Biologics have provided major advances in the treatment of 
plaque psoriasis. Little is known regarding adherence to biologics and factors 
associated with adherence in the Medicare population. This study is the first 
to examine adherence among Medicare patients with psoriasis newly initiating 
biologics. METhOdS: The 2009 to 2012 Medicare 100% files were used to iden-
tify patients who received infliximab, ustekinumab, adalimumab, or etanercept 
between 1/1/2010 and 12/31/2011. The date of first biologic prescription defined 
the index date. Patients were required to have fee-for-service Medicare Parts A, 
